Portland, OR, United States of America

Beth Habecker

This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignees: Oregon Health & Science University, Case Western Reserve University. Active years: 2019-2026.

USPTO Granted Patents = 3 

% Patents Active = 66.7

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2019-2026

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Beth Habecker: Innovator in Heart Disease Treatment

Introduction

Beth Habecker is a prominent inventor based in Portland, OR (US). She has made significant contributions to the field of medicine, particularly in the treatment of heart disease and injury. With a total of 3 patents, her work has the potential to impact many lives.

Latest Patents

Habecker's latest patents focus on innovative methods for treating heart disease and injury. One of her patents describes a method that includes administering a therapeutic agent that inhibits the catalytic activity, signaling, and function of PTPσ. This approach aims to provide new avenues for effective treatment in patients suffering from heart conditions.

Career Highlights

Throughout her career, Beth Habecker has worked with esteemed institutions such as Case Western Reserve University and Oregon Health & Science University. Her research and inventions have garnered attention in the medical community, showcasing her dedication to advancing healthcare solutions.

Collaborations

Beth has collaborated with notable colleagues, including Bradley T. Lang and Jerry Silver. These partnerships have enriched her research and contributed to the development of her innovative patents.

Conclusion

Beth Habecker stands out as a dedicated inventor whose work in heart disease treatment exemplifies the impact of innovation in medicine. Her contributions continue to pave the way for advancements in healthcare.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…